Los Angeles, CA—ChromaDex Corp. announced in a press release that it has received regulatory authorizations to sell its patented nicotinamide riboside chloride (branded Niagen) to consumers in the European Union and in Australia. As the regulatory applicants and innovators, ChromaDex benefits from market exclusivity in Australia until December 2021 and...
Los Angeles, CA—ChromaDex Corp announced in a press release the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. The trial will assess the potential of Niagen, ChromaDex’s branded nicotinamide riboside ingredient, to enhance the effects of...
Los Angeles--ChromaDex Corp. announced in a press release that its Tru Niagen (nicotinamide riboside) product is now available in all seven Whole Foods Market locations across Ontario, as well as select Pure Pharmacy locations, Fullscript Canada, and online. “Whole Foods’ dedication to bringing innovative, quality health and wellness products to its...
Los Angeles, CA—ChromaDex Corp. announced in a press release that a new study has further validated the safety and efficacy of ChromaDex’s proprietary form of nicotinamide riboside (NR), Niagen. The press release notes that, besides being the largest study on NR to date, it is the first clinical trial to...
Iowa City, IA--A new animal study from researchers at the University of Iowa found that giving nursing rodents a supplemental form of vitamin B3 (nicotinamide riboside; NR) lead to physical and behavioral benefits for the moms and their babies. In the study, published in Cell Reports, mother mice given NR...
Irvine, CA - ChromaDex Corporation is expanding. The nutraceutical company devoted to improving the way people age has launched TRU NIAGEN™ in Singapore with its retail partner, Watsons. This is the second Asian market - besides Hong Kong - to offer the dietary supplement. Watsons introduced the supplement in stores...
Irvine, CA — Research published in the journal Nature showed promise that nicotinamide riboside (NR) may help lower levels of amyloid deposits and improve mitochondrial energy production and memory in mice with Alzheimer’s Disease. Dr. Johan Auwerx and colleagues at the Ecole Polytechnique Federale de Lausanne in Switzerland conducted a...
Irvine, CA — ChromaDex announced its financial results for the first quarter (Q1) of 2017 ending on April 1, 2017. Net sales for Q1 2017 were $4.4 million, compared to the Q1 2016 which were $7.3 million, a 39% decrease. The firm attributes this decrease to dropping its largest customer...
Irvine, CA — ChromaDex Corp. announced today that its chief executive officer and co-founder, Frank Jaksch, will present at Cowen and Company’s 3rd Annual Future of the Consumer Conference: Convergence & Disruption. ChromaDex is a publicly traded natural products company, best known for its industry standard phytochemical testing laboratories and...
